Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy

被引：0
|
作者：
Charkviani, Mariam
Vaughan, Lisa E.
Sandahl, Tyler B.
Lin, Yi
Leung, Nelson
Herrmann, Sandra M.
机构：
[1] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA
[2] Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA
[4] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7542
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Chimeric antigen receptor T cell therapy for multiple myeloma
    Hasegawa, Kana
    Hosen, Naoki
    INFLAMMATION AND REGENERATION, 2019, 39 (1)
  • [42] CAR T-cell therapy for relapsed or refractory multiple myeloma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (06): : E297 - E297
  • [43] Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies
    Nishimura, Noriko
    Mailankody, Sham
    Nemirovsky, David
    Derkach, Andriy
    Costa, Bruno Almeida
    Farzana, Tasmin
    Shaikh, Aisha
    Latcha, Sheron
    Gutgarts, Victoria
    Jurgens, Eric M.
    Firestone, Ross S.
    Nath, Karthik
    Chung, David J.
    Landau, Heather J.
    Scordo, Michael
    Shah, Gunjan L.
    Shouval, Roni
    Hashmi, Hamza
    Hultcrantz, Malin
    Korde, Neha
    Lesokhin, Alexander M.
    Shah, Urvi A.
    Tan, Carlyn Rose
    Giralt, Sergio A.
    Usmani, Saad Z.
    Rajeeve, Sridevi
    BLOOD, 2024, 144 : 6944 - 6945
  • [44] Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy
    Ahmed, Nausheen
    Caimi, Paolo
    Reese, Jane S.
    Otegbeye, Folashade
    Patel, Seema
    Schneider, Dina
    Boughan, Kirsten M.
    Cooper, Brenda
    Gallogly, Molly
    Kruger, Winfred
    Worden, Andrew
    Kadan, Michael
    Lopes, Filipa Blasco Tavares Pereira
    Sharma, Ashish
    Malek, Ehsan
    Metheny, Leland
    Tomlinson, Benjamin
    Wald, David
    Sekaly, Rafick-Pierre
    Orentas, Rimas
    Dropulic, Boro
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S275 - S276
  • [45] EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/ REFRACTORY T-CELL LYMPHOMA
    Su, Guoai
    Yang, Fan
    Shi, Hui
    Liu, Rui
    Li, Ruiting
    Xu, Teng
    Feng, Shaoma
    Zheng, Peihao
    Guo, Yuelu
    Ma, Lixia
    Deng, Biping
    Ke, Xiaoyan
    Hu, Kai
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 196 - 197
  • [46] Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia
    Myers, Regina M.
    Fitzgerald, Julie
    Elgarten, Caitlin W.
    Getz, Kelly D.
    Li, Yimei
    Hogan, Jonathan
    Dinofia, Amanda
    Burrows, Evanette K.
    Aplenc, Richard
    Grupp, Stephan A.
    Laskin, Benjamin
    Maude, Shannon L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [47] HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
    Lebel, Eyal
    Asherie, Nathalie
    Kfir-Erenfeld, Shlomit
    Grisariu, Sigal
    Avni, Batia
    Elias, Shlomo
    Assayag, Miri
    Dubnikov-Sharon, Tali
    Zimran, Eran
    Shaulov, Adir
    Pick, Marjorie
    Cohen, Cyrille
    Stepensky, Polina
    Gatt, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S22 - S22
  • [48] Acute kidney injury following chimeric antigen receptor T-cell therapy: Epidemiology, mechanism and prognosis
    Yang, Yang
    Luo, Kaiping
    Xu, Gaosi
    CLINICAL IMMUNOLOGY, 2024, 266
  • [49] Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
    Qiu, Lei
    Zhu, Feng
    Wei, Guoqing
    Wu, Wenjun
    Yang, Luxin
    Hu, Yongxian
    Huang, He
    REGENERATIVE THERAPY, 2020, 14 : 271 - 274
  • [50] Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Yamamoto, Chihiro
    Minakata, Daisuke
    Yokoyama, Daizo
    Furuki, Shuka
    Noguchi, Atsuto
    Koyama, Shunsuke
    Oyama, Takashi
    Murahashi, Rui
    Nakashima, Hirotomo
    Ikeda, Takashi
    Kawaguchi, Shin-ichiro
    Hyodo, Kazuki
    Toda, Yumiko
    Ito, Shoko
    Nagayama, Takashi
    Umino, Kento
    Morita, Kaoru
    Ashizawa, Masahiro
    Ueda, Masuzu
    Hatano, Kaoru
    Sato, Kazuya
    Ohmine, Ken
    Fujiwara, Shin-ichiro
    Kanda, Yoshinobu
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 118.e1 - 118.e15
12345